Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating remibrutinib for its effectiveness and safety in treating patients with secondary progressive multiple sclerosis SPMS. This Phase III, randomized, double-blind, placebo-controlled study involves about 1275 participants who meet specific criteria, including an SPMS diagnosis and disability progression. The trial is designed to provide detailed data on remibrutinibs impact compared to placebo, with a focus on disability progression and other neurological measures. Participants are randomly assigned to receive either remibrutinib or a matching placebo tablet during the Core Part of the study, which is event-driven and double-blind. Following this, there is an Extension Part where all participants receive open-label remibrutinib tablets. Treatment is oral and involves ongoing monitoring to assess long-term effects and safety. Throughout the study, participants will undergo regular assessments including disability evaluations using the Expanded Disability Status Scale EDSS, Timed 25-Foot Walk, 9-Hole Peg Test, and cognitive testing with the Symbol Digit Modalities Test SDMT. Brain imaging will be used to track lesion development and brain atrophy. Safety will be closely monitored by recording adverse events. The total participation may span up to approximately five years, covering both core and extension phases.
Actively Recruiting
Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.
Actively Recruiting
Researchers are evaluating several investigational compounds for people with moderate to severe atopic dermatitis AD. This multicenter, randomized, double-blind, placebo-controlled Phase II platform study aims to assess the safety and effectiveness of these treatments, with Novartis Pharmaceuticals sponsoring the trial. The study focuses on improving skin symptoms and disease severity in participants diagnosed with AD for at least one year. The first treatment being tested is GHZ339, which will be given in different doses labeled A, B, C, and D. Participants are randomly assigned to study groups where they will receive a specific dose of GHZ339 or a placebo during the first treatment period. In the second treatment period, they continue with the same or adjusted dose, depending on their initial assignment. Placebo recipients in the first period will receive one of the GHZ339 doses during the second period. During the study, participants will have assessments including the Eczema Area and Severity Index EASI to measure disease changes, along with Investigator Global Assessment IGA scores at baseline and at 16 weeks. Researchers will monitor safety through laboratory tests and clinical evaluations. The total duration participants are followed corresponds to the treatment and assessment periods, and the main focus is tracking improvements in skin condition and overall disease status.
Actively Recruiting
Researchers are evaluating a new combination treatment of Sigvotatug Vedotin plus pembrolizumab compared to pembrolizumab alone in people with non-small cell lung cancer NSCLC that has high levels of PD-L1 protein. This protein can limit the bodys immune response to cancer. The study focuses on participants with advanced NSCLC Stage 3 or 4 who have PD-L1 expression in over 50% of their cancer cells and who are eligible for pembrolizumab treatment. All participants will receive pembrolizumab through an intravenous infusion every six weeks at the study clinic. Half of the participants will also receive Sigvotatug Vedotin as an intravenous infusion every two weeks alongside pembrolizumab. Participants may continue pembrolizumab treatment for up to about two years, while those receiving Sigvotatug Vedotin can continue until their cancer no longer responds to treatment. During the study, participants will visit the clinic regularly for monitoring, including assessments of overall survival and progression-free survival over approximately two years. The research team will evaluate how well participants respond to treatment and monitor side effects. Additional laboratory tests will assess drug levels and immune responses. The total study participation may last up to four years, with ongoing evaluations to measure treatment effects and safety.